Purity is the most commonly cited quality metric for research peptides, and the percentage figure is often the first — and sometimes only — thing researchers examine when evaluating supplier documentation. Whether a given purity level is adequate for a specific research application depends on context that the percentage alone cannot convey.
How purity is measured: HPLC fundamentals
Peptide purity is almost always determined by reversed-phase high-performance liquid chromatography (RP-HPLC). In this method, the sample is injected into a column packed with a hydrophobic stationary phase. Components of the sample interact with the stationary phase to varying degrees and elute at different times, detected by UV absorbance (typically at 214nm or 220nm, where the peptide bond absorbs). The purity percentage is calculated as the area of the main (target) peak divided by the total area of all detected peaks, multiplied by 100.
This means that "purity" as stated on a CoA is detector-purity: the proportion of UV-absorbing material at the detection wavelength that corresponds to the target compound. It is not a direct measure of the absolute quantity of the target compound in the sample, nor does it account for UV-transparent impurities that may be present but undetected.
What impurities actually are
Peptide impurities arise primarily from the chemical synthesis process. Solid-phase peptide synthesis (SPPS) involves assembling the peptide chain one amino acid at a time on a solid resin support. At each coupling step, the reaction is not 100% efficient. This produces:
Deletion sequences: peptides missing one or more amino acids due to incomplete coupling. A deletion sequence from BPC-157 would be a 14-amino acid peptide identical to BPC-157 except for one missing residue. It has a different molecular weight, a different HPLC retention time (usually), and different biological properties.
Truncated sequences: peptides where synthesis terminated early, producing shorter chains. Like deletion sequences, these have different molecular weights and properties.
Modified residues: oxidised methionines, deamidated asparagines and glutamines, or other chemically modified amino acids resulting from harsh synthesis conditions or storage. These may be difficult to separate by HPLC and may have significantly different receptor binding properties.
Residual reagents: protecting groups, coupling reagents, or scavengers used in synthesis that were not fully removed in the cleavage and purification process. These are typically small molecules rather than peptide-related impurities.
When the difference between 98% and 99% matters
For most exploratory preclinical research purposes, 98% purity is considered acceptable. The practical impact of the impurity fraction depends on: the biological activity of the impurities (a related sequence with partial receptor activity can confound dose-response results); the dose being studied (at very high doses, a 2% impurity may reach pharmacologically relevant concentrations); and the endpoint being measured (receptor binding assays are more sensitive to active impurities than histological endpoints).
For research focused on precise dose-response relationships, mechanistic studies at low concentrations, or comparative studies across multiple batches, higher purity (≥99%) reduces a potential variable. For receptor binding studies in particular, even small amounts of a related competing sequence can distort Ki calculations.
Consistency matters as much as the number
For longitudinal research across multiple experiments or cohorts, the consistency of purity across batches is arguably more important than the absolute level. A study conducted with 98.2% pure BPC-157 from Batch A and then repeated with 95.8% pure material from Batch B is not reproducible, even if the nominal dose in both cases is identical. The effective dose of the target compound has changed by approximately 2.5%.
This is why batch numbers and batch-specific CoAs matter. A supplier who provides a single purity figure for all stock of a compound cannot tell you whether the material you ordered from them last month has the same purity as what you ordered this month.
What to ask about purity
When evaluating purity data from any supplier, the relevant questions are: What HPLC method was used (column, gradient, detection wavelength)? Is the purity figure batch-specific or a general specification? Is identity also confirmed (i.e., is there mass spectrometry data)? Can you provide the actual chromatogram, not just the percentage? These questions separate documentation that reflects genuine analytical work from documentation that does not.